MedElevator Войти в исследования
← Поиск публикаций

DOI 10.57264/cer-2026-0126

Медицинская библиотека · Journal of comparative effectiveness research · 2026

Comparative cost analysis of Eluvia™ versus Zilver® PTX® in treating femoropopliteal peripheral artery disease utilizing real-world data.

Genovese Elizabeth A, Williams Abimbola O, Sato Ryoko, McGovern Alysha M, Jaff Michael R

СтатьяПеревод пока не подготовлен

Аннотация

Aim: To compare the hospital-based costs among patients with femoropopliteal artery (FPA) disease treated with Eluvia™ versus Zilver® PTX® drug-eluting stents using a large real-world USA hospital database. Materials & methods: This retrospective study included adults in the Premier Healthcare Database who underwent lower extremity FPA endovascular revascularization with Eluvia or Zilver PTX between 1 April 2019 and 31 March 2022. Total hospital-based costs during the index procedure and cumulative 1- and 2-year post-discharge follow-up were compared using multivariable generalized linear models adjusted for age, sex, race and baseline chronic limb-threatening ischemia (CLTI) status. Prespecified subgroup analyses were conducted by care setting (hospital inpatient and hospital outpatient) and among patients with chronic kidney disease (CKD) and CLTI.

Results

A total of 7208 patients were included, comprising 4218 treated with Eluvia and 2990 treated with Zilver PTX. Patients treated with Eluvia had a higher prevalence of several comorbidities, including congestive heart failure and CKD. Unadjusted mean hospital-based index procedure costs were similar between groups (Eluvia, $28,631 vs Zilver PTX, $28,359; difference, -$272; p = 0.7233). After adjustment, mean index procedure hospital-based costs did not differ significantly between treatment groups ($30,031, p = 0.8491). However, Eluvia was associated with lower adjusted cumulative hospital-based costs at the 1-year (difference, $4,017; p = 0.0066) and 2-year (difference, $6250; p = 0.0021) follow-up. Similar associations were observed in the hospital inpatient and CKD subgroups, whereas no statistically significant differences were observed in the CLTI subgroup.

Conclusion

Across patients undergoing femoropopliteal endovascular revascularization, Eluvia was associated with significantly lower post-discharge cumulative hospital-based follow-up costs than Zilver PTX while index procedure costs were comparable. These findings reflect hospital-based costs captured within participating hospitals and do not include medication costs or costs of care received outside the Premier Healthcare Database; therefore, they should not be interpreted as total healthcare costs.

Для цитирования: Genovese Elizabeth A, Williams Abimbola O, Sato Ryoko, McGovern Alysha M, Jaff Michael R. Comparative cost analysis of Eluvia™ versus Zilver® PTX® in treating femoropopliteal peripheral artery disease utilizing real-world data.. Journal of comparative effectiveness research. 2026. DOI: 10.57264/cer-2026-0126.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.